Intensive care patients with renal failure Not Applicable
Conditions
Interventions
Every patient will be observed for 72 hours after the start of the Ci-Ca CVVHD treatment. The participation in the study and the data collection will be terminated before 72 hours if the patient does
Sponsors
Fresenius Medical Care (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients (at least 18 years old, both males and females) treated on intensive care unit (ICU) due to renal failure requiring CVVHD and citrate anticoagulation (treatment with the multiFiltrate Ci-Ca System®) 2. Patient (or his legal representative or the next of kin - according to the local requirements) written informed consent
Exclusion criteria
Exclusion criteria: 1. Use of regional citrate anticoagulation in the period of 72 hours preceding the enrolment in the study 2. Concomitant participation in another clinical trial 3. Previous participation in the same study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main end-points for the safety evaluation is the occurrence of citrate metabolic complications (hypocalcemia, hypercalcemia, alkalosis, acidosis). For the efficacy evaluation main end-points are: the percentage of functioning filters after 72 treatment hours and post-filter ionized calcium. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
Austria, Germany, Norway, Switzerland, United Kingdom
Outcome results
None listed